HIMS vs SYRE
Hims & Hers Health vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
HIMS
Hims & Hers Health
52
Watch
VS
SYRE
Spyre Therapeutics, Inc.
67
Buy
| Metric | HIMS | SYRE |
|---|
| AI Score |
52
|
67
|
| Price |
$29.92
|
$95.14
|
| P/E Ratio |
-52.05×
|
-55.06×
|
| ROE |
23.7%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
64.7%
|
0.0%
|
| Debt / Equity |
4.77×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.0
|
59.9
|
| Beta |
2.415
|
3.026
|
| Expected Upside |
+0.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for HIMS versus SYRE.
SYRE leads by 15 points.
SYRE scores 67/100 (Buy) versus HIMS at 52/100 (Watch).
HIMS Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case. Value Analyst remains cautious — price-to-book of 13.7x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 32.8% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 13.7x prices in significant intangible value — Value
- ROE of only -2.5% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 1.80 adds balance-sheet risk to the value case — Value
SYRE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical